Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice
Research output: Contribution to journal › Article › Research › peer-review
3Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice'. Together they form a unique fingerprint.
Keyphrases
Medicine and Dentistry
Nursing and Health Professions
Pharmacology, Toxicology and Pharmaceutical Science